The Challenge

To combat disease, we need to look beyond genomics to the study of proteins, lipids, metabolites and other molecules that have the potential to be more indicative of disease.

In absence of high-resolution and throughput, pharmaceutical and clinical researchers struggle to identify clinically significant molecules when using existing separations technologies. These deficiencies limit the characterization of biologic therapeutics and slow biomarker discovery which are crucial to the development of more effective therapeutics and diagnostic assays.